Entities

Bruce Shook is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Vesper Medical, Intact Vascular, Neuronetics. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Daniele Andreini serves on Cleerly’s Scientific Advisory Board. Its directory identifies his cardiovascular imaging work at Ospedale Galeazzi–Sant’Ambrogio.

Louis Samson serves on Cleerly’s board and is identified as Platinum Equity’s co-president, with experience directing its investment and operating activities.

Bob Paulson is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Sonex Health, VentureMed, NxThera. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Lee Cooper serves on Cleerly’s board and is identified as AssistRx’s CEO. He previously led US Radiology. This is distinct from the Delos Capital biotechnology investor.

Tim Patrick is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Cartiva, Proxima Therapeutics. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Tripp Peake serves on Cleerly’s board and co-founded LRVHealth. His earlier experience includes Kestrel, MassVentures and Science Park Associates. Co-founder and managing partner of LRVHealth, founded in 2000. Previously a partner at Kestrel Ventures and founder and chief executive of MassVentures, investing in research and healthcare spinoffs, following leadership of Science Park Associates in New Haven.

Oscar Munoz serves on Cleerly’s board. He previously led United Airlines and held senior finance and operating positions including at CSX. Current Salesforce primary-source qualification: Oscar Munoz is a Salesforce board director. He has served on Salesforce’s board since January 2022 after membership of its global advisory board. Earlier he was United Airlines CEO and held operating leadership positions at CSX.

Michal Sofka is Cleerly’s Chief Technology Officer. His background includes AI research for portable MRI and work at Butterfly Network, Cisco and Siemens Healthineers. He earned a computer science PhD at Rensselaer Polytechnic Institute and has experience applying deep learning to cardiac CT.

Rich Mott is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Relievant Medsystems, Kyphon. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Salima Merani is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Knobbe Martens. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Christine Pellizzari is Cleerly’s Chief Legal Officer. She previously served as Science 37’s chief legal and human resources officer, including through its 2021 public listing and 2024 acquisition. Her experience spans public biotechnology legal and business leadership.

Amit Relia is Chief Regulatory Officer at Cleerly. He previously led quality and regulatory compliance at iRhythm, worked on robotic medical devices at Intuitive, and supported Apple Health’s ECG and wearable software regulatory programs.

Andrew Levitch is Cleerly’s Chief Financial Officer. Its company biography also identifies his financial consulting work at FLG Partners, his founding of Finategy and sixteen years at Merck. The published role does not establish that this is a full-time employee appointment.

Angela MacFarlane is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Voyant Biotherapeutics, ForSight Vision 4, ForSight Vision 5. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Parker Cassidy is Cleerly’s Chief Operating Officer. He previously was a partner at Sands Capital and worked at Mitra Biotech, Becton Dickinson and Upstate Biotechnology. He studied mechanical engineering at Boston University and earned an MBA at UVA Darden. His former employer’s institutional investment is not recorded as a personal investment.

Kimberly McCombs is Chief Strategy Officer at Cleerly and was its first employee after working with James Min at Weill Cornell. Her work covers partnerships, client services and business intelligence. She studied at the University of Arkansas and earned a healthcare administration master’s degree at Ohio University.

Matt Likens is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes GT Medical Technologies, Ulthera. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Malik Kahook is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes SpyGlass Pharma, ClarVista Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Udo Hoffmann is Cleerly’s Chief Medical, Scientific and AI Officer, as identified in its current leadership directory. He previously led cardiovascular imaging at Massachusetts General Hospital and was a Harvard radiology professor. His research includes ROMICAT, PROMISE and REPRIEVE. He earned a medical degree at Leipzig and an MPH at Harvard.

James K. Min is Cleerly’s founder and CEO. A cardiovascular imaging researcher, he previously directed the Dalio Institute at NewYork-Presbyterian and was a professor at Weill Cornell. He studied at the University of Chicago and Temple University and completed cardiovascular training at Chicago. He founded Cleerly in 2017. James Min is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Cleerly Health, Dalio Institute of Cardiovascular Imaging. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Jim Hartman is Chief Commercial Officer of Cleerly. He previously led health-system sales at Livongo and continued at Teladoc following its acquisition of Livongo. Earlier work included cardiovascular commercial roles at Maquet/Getinge and Boston Scientific/Guidant. He earned an MBA from NYU Stern.

Kevin Hykes is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes CVRx, Bardy Diagnostics, Relievant Medsystems, Cameron Health. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Earl Fender is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Nalu Medical, VertiFlex, J&J DePuy Spine. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Gene de Juan is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes ForSight Labs, UCSF. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Brad Bolzon is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Versant Ventures. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments. Brad Bolzon is Versant Ventures’ current Chairman, Managing Director. Leads firm strategy and global operations; previously headed Roche business development and held Lilly research and commercial-development roles. Holds Toronto pharmacology graduate degrees.

Jim Bullock is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Atritech, Endocardial Solutions. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Adam Berman is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Alleviant Medical, TVA Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Todd Berg is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Metavention, Torax Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Michael Ackermann is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Presidio Medical, Oculeve. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Neilly Newman is published by Vensana Capital as Executive Assistant. Minneapolis executive-support professional with earlier Versant, Polycom and Electronic Arts experience. Santa Clara psychology graduate.

Kristie Fox is published by Vensana Capital as Executive Assistant. Washington-area executive-support professional with earlier NEA and Kleiner Perkins life-sciences experience. Montana communication-studies graduate.

Elise Erkens is published by Vensana Capital as Executive Assistant. Minneapolis executive-support professional with earlier TripleTree and Värde Partners experience. Minnesota–Twin Cities child-psychology graduate.

Maggie Sullivan is published by Vensana Capital as Fund Finance Manager. Fund-finance professional supporting investment operations, financial analysis and investor relations, with prior J.P. Morgan private-bank experience and Wisconsin–Madison business education.

Steve Schwen is published by Vensana Capital as Partner and Chief Financial Officer. Venture-capital finance and operations executive with earlier Aduro, Split Rock and St. Paul Venture Capital finance leadership and KPMG experience. St. Thomas accounting graduate and inactive CPA.

Thomas Tu is published by Vensana Capital as Venture Partner. Physician and Vensana Innovation CEO with earlier Inari Medical CMO experience and interventional-cardiology practice. University of Virginia undergraduate and Harvard medical education; innovation platform leadership is separate from an invented fund.

Bill Hoffman is published by Vensana Capital as Venture Partner and Advisor. Medical-device operator and venture partner, formerly Inari CEO from 2015 to 2022 and Visualase CEO during 2008–2014. Visualase developed MRI-guided laser ablation for epilepsy and brain tumors; its pre-Vensana sale does not establish a Vensana fund investment. Also listed among Vensana advisors.

Petra Gorombei is published by Vensana Capital as Investment Professional. Clinical-evidence and operations specialist with earlier ZOLL cardiac clinical research experience. Cancer-research PhD from Paris Diderot and Duke executive MBA; published observer affiliations do not imply personal investment checks.

Allison King is published by Vensana Capital as Investment Professional. Healthcare investment professional with earlier Bank of America healthcare banking and hospital EHR consulting experience. Johns Hopkins biomedical-engineering graduate with a Duke MBA.

Mike Kramer is published by Vensana Capital as Partner. Operating and finance specialist who joined Vensana in 2021 after CRG and medical-device CFO/COO roles including Endologix, TriVascular and ATS Medical. North Dakota accounting graduate and inactive CPA.

Maria Berkman is published by Vensana Capital as Partner. Physician and investor with earlier Broadview and Longview cardiovascular and stroke investments, Monitor consulting and clinical training. Earned UCLA medical and MBA degrees.

Greg Banker is published by Vensana Capital as Partner. Medical-device investor and operator with prior Vertiflex and Navigant work spanning spine, pain intervention, neurology and robotic-surgery markets. Wisconsin–Madison biology graduate.

Kirk Nielsen is published by Vensana Capital as co-founder and Managing Partner. Medical-technology investor who co-founded Vensana in 2019 after leading Versant’s medtech practice. Earlier Medtronic, Fluidigm and Bain experience, with Harvard biology and MBA education; prior career investments are not assumed new Vensana fund checks.

Chief Information Security Officer, Main Line Health

CISO, CarGurus

Chief Growth Officer, Inrupt

Senior Manager of Revenue Technology, Shopify

Brand Director in Residence, Dow Jones

Software Engineer, AI Infrastructure, Google

Managing Director, Boston Meridian Partners

Astrid Noltemy advises Isomer Capital and sits on its investment committee. Her venture-capital career began in the 1980s and includes Cambridge Associates, Highland Capital Partners and Charles River Ventures. Her existing Glasswing Ventures adviser affiliation is preserved independently; this Isomer role does not replace it.

Chief Marketing Officer, Rocket Software

Founder & Partner, Avoca Partners

Principal, Big Digital Idea Consulting

Head Technology & Services, Investment Banking, Raymond James Financial, Inc.

Chief Information Security Officer & Chief Data Officer, Rockefeller Capital Management

Adjunct Lecturer in Public Policy / Security Technologist, Harvard Kennedy School

Fmr. CMO

Principal, Avire Finance USA

Chief Strategy & Corporate Development Officer, Everfox

Founder and CEO, The Athena Alliance

Senior Advisor, Fmr CMO, BCG, Aetna/CVS

Vice President of AI Applications & Platforms, Salesforce

Vice President of Engineering, Cisco

VP of Product Management, Microsoft Fabric, Microsoft

Professor, Stanford/MIT Media Lab Alex Pentland is a published Xfund faculty/advisory affiliate. The directory supplies this professional context: Alex Pentland Toshiba Professor of Media, Arts, and Sciences at MIT. This undated published affiliation is scoped to the Xfund advisory/community network; it does not establish an investment-partner appointment, cash contribution, personal check or independently verified current outside employment.

Director, MIT Ethical AI Initiative

Distinguished Professor of Information Technology, Babson College

SVP for AI & Data Strategy, Northeastern University/Institute for Experiential AI

Deputy CISO, Cummins Engine

Co-Founder & President of Marketing, Klaviyo

CIO, Gilder Office for Growth LLC

SVP of Engineering & CISO, Dutchie

Vice Chair of the Board of Directors, MSC Industrial Supply Co

President & CEO, Ninjio

Senior Vice President of AI Inference, Cerebras Systems

Managing Director, Rockefeller Global Family Office

Director of Strategic Investments, Ligo Partners LLC

SVP of Data, AI/ML, Engineering, Stitch Fix

Vice President and General Manager – Americas, HPE Aruba Networking

SVP, Head of Information and Data Security, GeneDx

Chief Technology Officer, Ziff Davis

Chief Product Officer, DoiT International

Global Business Leader & Board Member; Former President, Peacock & Hulu

Founder & CEO, Coretelligent

CRO, Nebius

Chief Commercial Officer, Four Seasons

CFO Designate, Reading; Former Investment Banker, Guggenheim Partners

Chief Commercial Officer, Convera; Former Chief Operating Officer, North America, Google

Chief Information and Technology Officer, The Kraft Group & Affiliates

Fmr. President & Chief Clinical Officer, Massachusetts General Hospital

Former Chief Technology Officer, Universal Filmed Entertainment Group

Chief ML Scientist, SVP ML/AI Eng. Tubi

Co-Founder, COO, Lighty AI; Former Director of Product Strategy & Operations, Google AI

CISO, Abnormal

Marketing Advisor / CMO, Data.org

Engineering Lead, Google

Chair & Executive Director, Boston Children’s Hospital

Fmr Senior Vice President – Data, AI, and Digital, Guardian Life

Founder & Principal, Cisohive

Senior Staff Software Engineer, Google

Co-founder and COO, Observo AI – a SentinelOne Company

Global CTO, Intact Insurance Specialty Solutions

Non-Executive Director, HSBC, YouGov

Founder and Managing Partner at Glasswing Ventures and former GSK board member. Listed in Asepha’s joint board/advisor section; her Glasswing position is an outside affiliation, not an employee title at Asepha.

Three-time successful CEO

Fmr. Tech Curator, TED Conferences

Inventor, the World Wide Web

Senior Director, AI Innovation and Agentic Automation, Responsible AI Products, Microsoft

Founder and CEO, Ascendant Network

Professor of Entrepreneurship, Harvard Business School

Former CMO, Dunkin’ and CEO, Digitas

SVP and Chief Data Officer, Centene Corporation

Dendrion Ventures, LLC is a Chicago medical-technology investor whose own website describes an evergreen-capital strategy. SEC2026 filings identify the LLC as manager of dedicated venture vehicles, including MadSci and Innoblative; separate Re-Emerge and Epitel vehicles name Tyler Wanke as executive. Northwestern's Kellogg Healthcare Club identifies Wanke as Dendrion's managing director. ReEmerge's September2026 SeriesA announcement confirms the firm as a neuroscience investor. Public sources do not publish a complete team directory, manager founding date or aggregate closed evergreen corpus. Individual SPV raises and fundraising targets are recorded separately and are not treated as the manager's company-level investment tickets.

John E. Runnells is published by The Vertical Group as a general partner. He joined the firm in 1992 after co-founding Paddington Partners, which invested in special situations and public healthcare companies. Earlier, he was a partner at Webster & Sheffield. He studied business at Pennsylvania State University and law at Harvard. Board affiliations in the older firm biography are not independently asserted as current.

William Woodford is Co-founder and Chief Technology Officer at Form Energy. Co-founded Form and develops low-cost electrochemical energy-storage systems. Previously led advanced R&D at 24M Technologies. Holds a materials-science doctorate from MIT and a bachelor’s degree from Penn State.

Ted Wiley is Co-founder & President at Form Energy. Co-founded Form and oversees manufacturing, supply chain, program management and safety. Previously co-founded Aquion Energy, held product leadership at MassChallenge and led McDonough Innovation. A former US Army infantry officer.

Wes Sloan is Chief Operating Officer at Form Energy. Leads company operations. Previously an executive vice president at Panasonic Energy North America overseeing its Nevada battery operation, and spent twelve years at Rolls-Royce, including in assembly and test operations.

Tobias Schmieg is Vice President, Product Engineering at Form Energy. Leads engineering for multi-day energy-storage products. Previously led product development at Gotion High-Tech and spent eight years developing electric-vehicle battery systems at BMW.

Christopher Reynolds is Vice President, Core Technology at Form Energy. Leads battery cell design, chemistry, process selection and early scale-up. Joined Form in 2020 after leading technology and operations at AFC Energy. Studied materials science and engineering at Queen Mary University of London.

Brian Lewis is Interim General Counsel at Form Energy. Leads legal and compliance work across commercial agreements, intellectual property, governance and employment. Previously an associate general counsel at Facebook and an Assistant US Attorney in Northern California.

RJ Johnson is Chief Commercial Officer at Form Energy. Leads commercial development, policy, analytics, project engineering and service operations. Previously led Tesla Energy operations and held origination leadership at NextEra Energy Resources. A former US Army officer.

Mateo Jaramillo is Co-founder and Chief Executive Officer at Form Energy. Co-founded Form Energy after leading products and programs for Tesla’s stationary energy-storage business. Previously a founding-team member and COO at Gaia Power Technologies. Studied economics at Harvard and theology at Yale.

Kristen Ilgenstein is Vice President & Corporate Controller at Form Energy. Leads accounting, financial reporting and controls. Previously advised manufacturing companies through her consulting practice, held controller and director roles at SunPower, and worked at KPMG.

Amy Higgins is Senior Vice President, People at Form Energy. Leads people strategy, hiring, rewards and employee development. Previously CHRO at Alert Innovation, with earlier leadership at Commonwealth Fusion Systems and Aquion Energy.

Navneet Govil is Chief Financial Officer at Form Energy. Leads finance, capital formation and investor relations. Previously Executive Managing Partner and CFO at SoftBank Investment Advisers. Earlier roles included CA Technologies, SunPower, Sun Microsystems, HP and Pfizer.

Marco Ferrara is Co-founder and Chief Digital Officer at Form Energy. Leads software, analytics, data, AI and IT. Previously led software and analytics at Form, energy optimization at IHI, and storage-software development at 24M Technologies. Holds doctorates from MIT and the University of L’Aquila.

Yet-Ming Chiang is Co-founder and Chief Science Officer at Form Energy. MIT materials-science professor and co-founder of Form Energy. His research addresses materials and energy storage. Previously co-founded Desktop Metal, 24M Technologies, A123 Systems and American Superconductor.

Catherine Carmichael is Vice President, Global Supply Chain at Form Energy. Leads supply-chain strategy, procurement, supplier development and logistics. Previously led supply-chain management for Tesla energy storage and solar, and worked at PowerAdvocate and Woods Hole Oceanographic Institution.

Sarah Bray is Vice President, Communications & Corporate Affairs at Form Energy. Leads corporate communications and policy work. Previously founded clean-energy communications firm Innovant Public Relations and led public affairs at Clean Line Energy.

Form Energy is an American deep-technology company developing and manufacturing rechargeable iron-air batteries for multi-day electricity storage. Its first commercial product is designed to discharge electricity continuously for 100 hours, using an electrochemical iron-oxidation and reduction cycle. The company also develops Formware grid-modeling software. Founded in2017 by Mateo Jaramillo, Ted Wiley, William Woodford, Yet-Ming Chiang and Marco Ferrara, it operates Form Factory1 in Weirton, West Virginia, with research and engineering operations in Massachusetts and California. Its current public leadership has15 named members, and the company reports more than1,000 employees. Its relevance to AI includes grid storage agreements serving data-center electricity demand and a digital organization responsible for software, analytics, data and AI initiatives; it is primarily an energy-storage technology business. Government grant awards, commercial supply agreements, manufacturing commitments and equity financing are distinct. The published SeriesA–G figures total USD1.97B; the issuer’s August2026 statement that total equity exceeds USD2B is retained without inventing an undisclosed balancing round.

Brandon Felkins is listed by Santé Ventures as Venture Fellow (Alumnus). Public team directory places him in Fellow Alumni; former Tangible co-founder and Stanford Biodesign educator.

Elisabet Rosas Canyelles is listed by Santé Ventures as Fellow (Alumna). Public team directory places her in Fellow Alumni; Stanford Impact1 program and bioengineering research experience.

Laura McMillian is listed by Santé Ventures as Office Manager. Joined 2022; leads office administration after roles at Woodbine Capital, Centre Lane, General Atlantic and Lime Rock Partners.

Mariel Bolhouse is listed by Santé Ventures as Fellow (Alumna). Public team directory places her in Fellow Alumni; historical venture fellowship rather than current employee status.

Rosemary Shults is listed by Santé Ventures as Fellow (Alumna). Public team directory places her in Fellow Alumni; historical venture fellowship rather than current employee status.

Shannon Czimskey is listed by Santé Ventures as Senior Financial Accountant. Joined 2021 to oversee daily accounting operations and support portfolio companies; previously Academic Programs International.

Stephane Peluso is listed by Santé Ventures as Venture Fellow / Entrepreneur-in-Residence (Alumnus). Public team directory places him in Fellow Alumni; historical venture incubation followed oncology leadership at Infinity and Ipsen.

Yelena Wetherill is listed by Santé Ventures as Venture Fellow / Entrepreneur-in-Residence (Alumna). Public team directory places her in Fellow Alumni; biotechnology alliance and clinical development experience at Novartis.

Alana Horowitz is listed by Santé Ventures as Senior Associate. Joined 2025 after McKinsey life-sciences consulting; researched brain aging and rejuvenation at UCSF.

Allie Knauer is listed by Santé Ventures as Venture Fellow. Medical technology engineer and Stanford Biodesign educator, previously SparkMed business development leader.

Auriel August is listed by Santé Ventures as Principal. Physician and biomedical engineer focused on medtech and healthcare services; trained at Stanford and Dartmouth and formerly worked at IDEO.

Brendan Boland is listed by Santé Ventures as Venture Fellow & Entrepreneur-in-Residence. Combined Santé/Oxford Science Enterprises fellowship; physician co-founder of Loci Orthopaedics with medical technology operating experience.

Charlene Tang is listed by Santé Ventures as Venture Fellow. Healthtech operator, Stanford Biodesign fellow and former Cyted commercial lead; co-founded AptaBridge Therapeutics.

Chas Juliano is listed by Santé Ventures as Controller. Joined 2023; oversees accounting and financial reporting after AtScale and Accomplice/Atlas Ventures finance roles.

Ian Rahwan is listed by Santé Ventures as AI Engineer. Joined 2026 after H-E-B Digital machine learning platform engineering; UT Austin neuroscience graduate with healthcare explainable-AI research.

Jake Rogers is listed by Santé Ventures as Head of Operations. Joined 2016; oversees operations after working on Santé Capital trade execution, reporting and portfolio monitoring.

Kyle Schroeder is listed by Santé Ventures as Senior Analyst. Joined 2025 after infrastructure finance at Starwood Property Trust and investment banking at Wells Fargo.

Mateo Vargas is listed by Santé Ventures as Senior Associate. Supports venture incubation after Stanford Biodesign and surgical robotics engineering at Verb Surgical and Auris Health.

Michael Gutbrod is listed by Santé Ventures as Principal. Joined 2021 in biotechnology investing after MIT research combining deep learning and stem-cell models of brain disorders.

Ryan Hall is listed by Santé Ventures as Associate. Joined 2022 after Carlyle deal execution and portfolio management; William & Mary finance graduate.

Brooke Jones is listed by Santé Ventures as Head of Capital Formation. Joined 2020 following capital raising leadership at Brooklands, Bank of America, Citi and Credit Suisse.

Diane Brouillard is listed by Santé Ventures as Head of Talent & Networks. Leads talent and recruitment initiatives after PwC executive networking and banking recruitment roles.

Hyegi Chung is listed by Santé Ventures as Director of Accel Singapore. Leads Asian healthcare venture building after Verily APAC operations and regenerative medicine entrepreneurship.

Jeff Crawford is listed by Santé Ventures as Head of Finance. Joined 2026 to lead finance and compliance following CFO roles at Gothams and NantWorks.

Michael Hoffman is listed by Santé Ventures as Senior Advisor. Co-founded Palamon Capital Partners and formerly led international investing at Warburg Pincus.

Thomas Krummel is listed by Santé Ventures as Venture Partner. Joined 2021; Stanford emeritus surgeon and Biodesign co-director with surgical simulation and robotics experience.

William Cohn is listed by Santé Ventures as Venture Partner. Cardiac surgeon and medical device inventor, BiVACOR chief medical officer and Texas Medical Center Medical Device Labs executive director.

Ashley Seehusen is listed by Santé Ventures as Venture Partner. Leads Santé Accel venture studio and formerly co-founded Nasus Medical; Stanford Biodesign educator.

Louis Bock is listed by Santé Ventures as Venture Partner. Joined 2014 in biotechnology investing after co-founding Scale Venture Partners and roles at Gilead and Genentech.

Douglas French is listed by Santé Ventures as Founding Managing Director. Co-founder and former Ascension Health chief executive and Ascension Ventures founder.

James Eadie is listed by Santé Ventures as Managing Director. Leads medical device investing; joined 2009 and previously practiced emergency medicine with the US Air Force.

Joe Cunningham is listed by Santé Ventures as Founding Managing Director. Physician co-founder in 2006 with prior Providence Health System and Ascension Health Ventures leadership.

Omar Khalil is listed by Santé Ventures as Managing Director. Leads Boston biotechnology practice; joined 2007 and returned2020 after pharmaceutical industry leadership.

Valtor Solutions provides construction material sourcing and procurement services for property developers in Southeast Asia, starting with the Philippines. It combines vetted supplier networks, architectural materials expertise, consolidated logistics and warehousing so developers can source building finishes and mechanical, electrical and plumbing products through one procurement process. Its platform supports material selection and requests for quotations, while its advisers help customers choose suitable, cost-efficient and sustainable building materials.

Virdalis develops animal feed protein from Wolffia globosa, a fast-growing species of duckweed. Its cultivation system manages water and nutrients, and its farmer production model grows and harvests duckweed for processing into protein meal for feed manufacturers and livestock producers. The company aims to provide a locally produced alternative to imported feed protein such as soybean meal, using less agricultural land and supporting more resilient feed supply chains. Virdalis is based in Singapore with operating activities in the Philippines.

WasteX develops modular biochar production equipment and services that turn agricultural biomass waste into useful products and carbon removal. Its carbonizers process crop residues with controlled biomass and syngas combustion; the company also supports equipment installation, operator training, biochar use in farming and carbon credit verification. Customers can apply biochar to soils and other agricultural uses rather than burn or discard residues. WasteX operates from Indonesia and India and serves local and international agricultural producers and carbon removal projects.

Zentide develops seaweed-based agricultural biosolutions to improve soil health and reduce reliance on synthetic inputs. Its Kaylix soil conditioner uses tropical seaweed bioactives, supported by research and field trials in Lombok, Indonesia. The company works with seaweed-growing coastal communities, farmers and distributors to bring these products to market and help farmers improve crop productivity and resilience. It launched Kaylix commercially in January 2026 and is expanding distribution across Indonesia.

Architect with more than 30 years of design, construction and property management experience; a Certified BERDE Professional.

Entrepreneur leading a construction sourcing and procurement business in Southeast Asia.

Agricultural sales leader with more than ten years of sales leadership experience.

Also known as JM Aujero; previously held leadership roles at GCash.

Architect advising on interior design, materials specification and sustainable residential and commercial projects.

Also named Zachary David Nice; leads strategy, commercial growth and regional expansion. Previously a regional director at DGX.

Operating advisor of HCAP Partners specializing in healthcare operations, integration, value creation and corporate transactions. Previously held leadership roles at Gentiva/Kindred, Haven Health Care and Mission Healthcare, the latter a former HCAP Fund IV portfolio company.

Operating advisor of HCAP Partners with healthcare and technology operations, cybersecurity, turnaround and acquisition-preparation experience. Her biography describes leadership at Chordline Health and previous chief executive roles at Casamba and Brighton Rehabilitation. Historical executive positions are not inferred current appointments.

Operating advisor of HCAP Partners focused on technology, organizational change and digital transformation. Her career includes executive, board and advisory work involving Redbox/Coinstar, MOD Pizza, TrueBlue, Tealium and TIBCO; these historical organizations are not asserted as simultaneous current employers.

Operating advisor of HCAP Partners with growth-company operations and technology experience. Previously led Enli Health and held executive roles at Intel, NEC Computer Services and eFusion. His background includes governance, corporate transactions, risk management and organizational development.

Operating advisor of HCAP Partners with extensive middle-market investing, transaction structuring, operational and board experience. Previously co-founded Bunker Hill Capital and held leadership roles at Kinsman Capital, Pacific Corporate Group and Charterhouse Group. Career investment statistics span prior employers and are not HCAP fund assets.

Senior director of impact of HCAP Partners since March 2022, leading its Gainful Jobs Approach, impact management, research and portfolio workplace initiatives. Previously led Pacific Community Ventures’ research and consulting practice. He studied managerial economics at UC Davis.

Senior associate of HCAP Partners, which she joined in 2023, supporting origination, underwriting, structuring and monitoring of healthcare, technology and services investments. Previously worked in corporate and real-estate credit at Morgan Stanley and underwriting and portfolio management at Santander. She holds Columbia Business School, USC and China University of Political Science and Law degrees.

Analyst of HCAP Partners, which he joined in 2024, supporting investment due diligence and transaction execution. Previously worked in Stifel private capital advisory. He holds a finance degree from San Diego State University; capital raised during prior employment is not an HCAP fund size.

Senior partner of HCAP Partners, which he joined in 2022. He originates, structures, closes and monitors investments across healthcare, logistics, manufacturing and other sectors. Previously a principal and investment committee member at CVF Capital Partners, a Tresalia Capital investment professional, entrepreneur and Santander asset-management analyst. He holds Kellogg and Tec de Monterrey degrees.

Anna Roberts is listed in ShangBay Capital’s current public directory as Analyst. Further career biography is not published on the linked directory.

Senior partner of HCAP Partners since joining the firm in February 2013, responsible for origination, structuring, closing and portfolio monitoring. Previously worked at DBI Capital, Citigroup fixed-income private placements and the Economic Development Bank for Puerto Rico. He holds Wharton and Columbia business degrees. His current firm biography lists healthcare, cybersecurity and software portfolio board responsibilities.

Senior partner of HCAP Partners, which he joined in May 2009. He oversees investment origination, structuring, closing, monitoring, investor relations and impact initiatives. He led the manager’s 2019 CortiCare investment. His current biography lists portfolio board or observer responsibilities at Integrated Diagnostic Services, BetterNight, Apprio, Puzzle Healthcare, Chordline and Myndshft. Previously an analyst at the Reserve Bank of Zimbabwe, he holds business and finance degrees from the University of San Diego and University of Zimbabwe.

Vice president of HCAP Partners, which she joined in September 2022. Her work includes origination, diligence, underwriting and investment monitoring; the firm lists an Apprio Health board observer role. Previously worked in credit analytics and regulatory capital at Morgan Stanley, asset-backed lending at Emigrant Bank and risk management at Citigroup. She holds Columbia mathematics and NYU business degrees.

Accounting and office administrator of HCAP Partners since June 2024, responsible for accounts payable and human-resources administration. Her prior accounting work includes Gurtin and PIMCO, integration work following an acquisition, reconciliation and financial reporting across multiple industries.

Olivia Sinkula is listed in ShangBay Capital’s current public directory as Associate. Further career biography is not published on the linked directory.

Vice president of HCAP Partners, which he joined in 2023. He originates, structures, closes and monitors debt and equity investments across healthcare, technology, industrial and business services sectors. Previously a vice president at CVF Capital Partners, he studied finance at Cal Poly San Luis Obispo and holds the CFA charter.

Executive assistant of HCAP Partners since March 2023, supporting firm administration and executive operations. Previously served for seventeen years as executive assistant to the CEO of Garden Communities.

John Dai is listed in ShangBay Capital’s current public directory as Associate. Further career biography is not published on the linked directory.

Managing partner of HCAP Partners, which he joined in June 2007 after commercial banking and venture investment roles at Silicon Valley Bank and Comerica. He leads firm development and debt and equity investments in growth businesses. His current firm biography lists portfolio board and observer responsibilities including Pax Health, Lone Star Analysis, Xevant, Cubex Systems, Flume Water and IND.

Cindy Costello serves ShangBay Capital as Director of Finance & Administration. Published career biography: Cindy Costello is an accountant who has supported ShangBay since its establishment and manages its finance and administration. Her manager biography also identifies Laskey Costello and experience in business taxation, accounting and financial analysis. She earned a Cleveland State MBA and Dayton accounting degree.

Chief financial officer of HCAP Partners, overseeing fund financial operations, reporting, audit, regulatory compliance, investor financial matters and lender relationships. Previously worked in public accounting at BDO in the United States and South Africa. A Stellenbosch accounting graduate, he is a South African chartered accountant and California CPA.

HCAP Partners is a California private equity and mezzanine debt manager founded in 2000 as Huntington Capital and renamed in 2015. Based in La Jolla, it provides acquisition and growth financing to underserved lower-middle-market businesses across the United States, emphasizing healthcare, software, services and manufacturing. Its current published investment range is $5 million to $35 million, typically serving businesses with $10 million to $100 million in annual revenue. The firm supports portfolio operations and job quality through its Gainful Jobs Approach. Its neuroscience relevance is demonstrated by its 2019 investment in CortiCare, an EEG neurotelemetry and remote brain-monitoring provider, and its neuropathy-care portfolio. AI exposure is grounded in actual portfolio companies including Lumifi Cyber, which applies AI and machine learning to threat detection and remediation, Saphyre’s trade-data automation, and Aarista’s AI-supported post-acute care platform. The current public roster contains twelve staff and five separately identified operating advisors. Managed fund totals are not individual investment checks. Fund V’s published $353 million total includes anticipated SBA leverage; independently raised LP capital is not separately disclosed in the closing announcement.

Robert Kamen serves ShangBay Capital as Senior Advisor. Published career biography: Robert Kamen has biotechnology investing, scientific and executive experience. His manager biography describes Third Rock and Oxford Bioscience roles, Genetics Institute, Abbott and BASF leadership, and work on Humira development. He co-founded BioAssets and studied biophysics at Amherst and biochemistry and molecular biology at Harvard.

Andy Weimin Dai serves ShangBay Capital as Senior Advisor. Published career biography: Andy Weimin Dai works in healthcare informatics, clinical-data infrastructure and analytics, including natural-language processing and machine learning. His manager biography describes leadership at Providence and earlier informatics work at Adventist Health, IBM and Dell. These outside titles are published career information rather than independently dated appointments.

Mel Dong serves ShangBay Capital as Senior Advisor. Published career biography: Mel Dong is a former FDA specialist in premarket review and inspections who advises pharmaceutical and medical-device businesses on compliance. His manager biography identifies Blue Bell Consulting and industry training work. His education includes UNC business, Michigan State doctoral and Shanghai First Medical College medical studies.

Malcolm G. Munro serves ShangBay Capital as Senior Medical Advisor. Published career biography: Malcolm Munro advises on medical-device development, clinical research, regulatory issues and commercialization. His research concerns gynecology and minimally invasive treatment, including abnormal uterine bleeding. The manager biography identifies his consulting practice, UCLA academic affiliation and work establishing the Women’s Health Research Collaborative.

Yajun Xu serves ShangBay Capital as Senior Advisor. Published career biography: Yajun Xu has drug-discovery, biotechnology and corporate-development experience. The manager biography identifies Hongsen Investment, EpimAb and advisory or board relationships at Abcuro, Zai Lab and Hotspot. Earlier work includes ShangPharma, ChemPartner, Millennium and BASF. She earned a Brandeis biochemistry doctorate and trained at Harvard.

Michael Wallace serves ShangBay Capital as Venture Partner. Published career biography: Michael Wallace is a mechanical engineer and serial medical-device founder. His startups include DeVoro Medical, TW Medical, GW Medical and CardioProlific, which were acquired by major device companies. Earlier technical leadership includes Silk Road Medical, Baxano, Boston Scientific, BarrX and Target Therapeutics. He studied at Delaware and UC Davis.

Erik T. Engelson serves ShangBay Capital as Venture Partner. Published career biography: Erik Engelson has led medical-device companies including Dragon Vascular, Lucira Health and Medina Medical. Earlier experience includes The Foundry, Fluidigm, Versant and Institutional Venture Partners, and interventional-neuroradiology development at Target Therapeutics. He studied microbiology and bioengineering at UC San Diego and executive business at Stanford.

Chaucer Shen serves ShangBay Capital as Managing Partner. Published career biography: Chaucer Shen is a physician and medical-device investor. Before ShangBay he advised Legend Star on healthcare investments. His operating experience includes Asia-Pacific leadership at Stereotaxis and commercial or business-development roles at BarrX Medical, EV3, Boston Scientific and Medtronic.

Respond.io provides a customer conversation platform for businesses handling high volumes of consumer enquiries, sales and follow-up messages. It brings messaging channels, voice calls, email, customer history and CRM integrations into a shared workspace for human teams and autonomous AI agents. Its tools automate routing, campaigns and customer journeys, including answering questions, qualifying leads, updating CRM records and arranging bookings, so businesses can capture, convert and retain customers across channels. Founded as Rocketbots in Hong Kong in 2017, the company renamed itself respond.io in 2020 and is headquartered in Kuala Lumpur, Malaysia.

Co-founder and CEO of respond.io, previously at IBM, Google and Runtastic and former growth leader at NDN Group. Holds an MBA from the Chinese University of Hong Kong and a Reutlingen University science degree; co-chair of the Artificial Intelligence Society of Hong Kong.

Co-founder and CTO, leading development and technical innovation of the customer communications platform. Studied computer engineering at NUST and computer science at the University of Peshawar.

Co-founder and COO, leading growth and operations. MBA graduate of the Chinese University of Hong Kong, with earlier information management and knowledge transfer work at Kodak Alaris, Xaxis and Light Reaction.

PLD Space is a Spanish space transportation company developing launch vehicles and the industrial infrastructure needed to deliver satellites and other payloads to space. Its MIURA programme includes the MIURA 1 technology demonstrator, which flew in October 2023, and the MIURA 5 orbital launcher being developed for commercial missions. The company combines vehicle engineering, manufacturing, testing and launch operations, with an industrial base in Elche, Spain, and launch infrastructure at the Guiana Space Centre in French Guiana. Its wider development programme also includes the LINCE space capsule.

Leads strategy and public affairs. Holds a political science and sociology doctorate and public policy master’s; background includes military service, government advisory, national intelligence and state-owned real-estate strategy.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Executive president and published governance member; also serves on the Technical Advisory and Ethics & Compliance committees under his full name Ezequiel Sánchez Cascales. ESIC marketing graduate and ESCP MBA with experience in management education and business strategy.

Leads general services, with experience in management, operations, technology and business development at Inditex, Etnia Barcelona, MTNG Experience and Ferrovial Servicios.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Listed in PLD Space’s published committee composition table under the Technical Advisory Committee. Advisory membership is distinct from employment or a board seat.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Listed in PLD Space’s published committee composition table under the Technical Advisory Committee. Advisory membership is distinct from employment or a board seat.

Leads people and culture strategy, with experience in employee management and organizational change across healthcare, finance and technology. Also Ethics & Compliance Committee member under his full name José Andrés Sánchez Bueno.

CFO since 2022, responsible for financial strategy, operations and fundraising. ESCP Executive MBA with experience in finance for technology scaleups.

Listed in PLD Space’s published committee composition table under the Technical Advisory Committee. Advisory membership is distinct from employment or a board seat.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Aeronautical engineer and PMI-certified programme leader, with PLD Space since 2021. Oversees strategic programmes and previously managed MIURA 1. Also Technical Advisory Committee member under her full name María Jesús Alberola Puerto.

Full name Rafael Castro Padró. Aerospace engineer with more than 25 years of manufacturing experience, mainly at ITP Aero. Leads launcher production teams, industrial processes and vehicle integration.

Co-founded PLD Space with Raúl Verdú in 2011. Leads MIURA launcher and LINCE capsule technology development and acts as launch director. Studied biological sciences and aerospace engineering; also Technical Advisory Committee member under the full name Raúl Torres Berenguer.

Co-founded PLD Space in 2011. Industrial engineering background; leads business strategy, new opportunities and expansion.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Vidar Wendel-Hansen is published by SSI Strategy as NDA regulatory advisory expert. Physician and PhD with clinical-development, regulatory and medical-affairs experience in neuroscience, infectious disease and immune-mediated conditions.

Thomas Lönngren is published by SSI Strategy as NDA regulatory advisory expert. Regulatory strategy advisor and former EMA Executive Director from 2001 to 2011, with earlier Swedish Medical Products Agency leadership.

Sigrid Klaar is published by SSI Strategy as NDA regulatory advisory expert. Physician, PhD and oncologist with Swedish medicines-assessment and health-technology assessment experience, including EMA oncology and national reimbursement work.

Paula Salmikangas is published by SSI Strategy as NDA regulatory advisory expert. Advanced-therapy and biopharmaceutical regulatory expert, formerly chair of the EMA Committee for Advanced Therapies; advises on CMC and clinical-development requirements.

Patrick Salmon is published by SSI Strategy as NDA regulatory advisory expert. Pharmaceutical-medicine and rare-disease regulatory specialist with European agency and Trinity College Dublin teaching experience.

Mel Walker is published by SSI Strategy as NDA regulatory advisory expert. Commercial strategy and market-access advisor with earlier Roche, GSK and Otsuka experience, co-founder of BioPharma Futures.

Marianne Scheel Fjording is published by SSI Strategy as NDA regulatory advisory expert. Bioanalysis specialist with experience in pharmacokinetic, biomarker and immunogenicity assays and ICH M10 method-validation work.

Margarida Menezes Ferreira is published by SSI Strategy as NDA regulatory advisory expert. Biological-medicines and advanced-therapy regulatory expert with earlier Infarmed and EMA committee experience, advising on quality, comparability and manufacturing requirements.

Mads Hansen is published by SSI Strategy as NDA regulatory advisory expert. Hematologist and clinical-development expert with academic, regulatory and pharmaceutical experience; founder of ZEMA Pharma Consulting.

Karl-Heinz Huemer is published by SSI Strategy as NDA regulatory advisory expert. Regulatory advisor with neuroscience, ophthalmology, pediatric and orphan-drug experience, including EMA scientific-advice and pediatric-review work.

Jan Sjöberg is published by SSI Strategy as NDA regulatory advisory expert. Hematology and internal-medicine specialist with Swedish and Icelandic regulatory-agency experience in oncology and medicines assessment.

Frits Lekkerkerker is published by SSI Strategy as NDA regulatory advisory expert. Internal-medicine specialist and regulatory medical advisor, formerly chairing the Dutch Medicines Evaluation Board and serving on EMA committees.

Chantal Van Gils is published by SSI Strategy as Vice President, Evidence & Value (NDA regulatory network). Physician-scientist and SSI evidence-and-value leader integrating clinical evidence with regulatory, health-technology assessment and payer requirements.

Björn Carlsson is published by SSI Strategy as Vice President, Regulatory Science (NDA regulatory network). Regulatory-science leader with clinical-immunology experience and earlier Swedish Medicines Agency and EMA advanced-therapy assessment roles.

Albert L. Kraus is published by SSI Strategy as NDA regulatory advisory expert. Regulatory drug-development advisor with oncology, rare-disease and immunology experience, including earlier Pfizer work and published GDS Partners leadership.

James Wooldridge is published by SSI Strategy as Independent Executive Advisory Network member. Clinical drug developer with first-in-human and later-stage trial experience, published as Immunitas Therapeutics CMO.

Sharief Taraman is published by SSI Strategy as Independent Executive Advisory Network member. Child neurologist and clinical-informatics physician, published as Cognoa CEO. Works on autism diagnostic AI and pediatric neurology; network membership is not SSI employment or a newly inferred cash investment.

Sukumar Nagendran is published by SSI Strategy as Independent Executive Advisory Network member. Gene-therapy and rare-disease physician executive with experience in Zolgensma development and published Taysha Gene Therapies R&D leadership.

Chris Morabito is published by SSI Strategy as Independent Executive Advisory Network member. Physician-scientist with pediatric critical-care experience and later pharmaceutical-development roles at Merck, Sanofi and Takeda, including neuroscience portfolio strategy.

Fred Grossman is published by SSI Strategy as Independent Executive Advisory Network member. Physician and CNS therapeutic-development executive with experience across psychiatric and neuroscience programs at large pharmaceutical companies.

Ilan Ganot is published by SSI Strategy as Independent Executive Advisory Network member. Biotechnology executive with earlier investment-banking experience, co-founder of Solid Biosciences and published Alesta Therapeutics leadership.

Greg Fiore is published by SSI Strategy as Independent Executive Advisory Network member. Physician, former McKinsey consultant and SSI co-founder whose published biography dates founding to 2011. Later founded Fiore Healthcare Advisors and co-founded Exacis Biotherapeutics; company sales are not personal investment tickets.

Dan Bloomfield is published by SSI Strategy as Independent Executive Advisory Network member. Physician and cardiovascular drug developer with earlier Columbia academic work and Merck clinical-development leadership; trained as an Oxford Rhodes Scholar.

Howard Berman is published by SSI Strategy as Independent Executive Advisory Network member. Neuropharmacology PhD and biotechnology entrepreneur associated with Coya Therapeutics and ReAlta Life Sciences. Clinical-development and external board experience are distinct from SSI employment.

Usman Azam is published by SSI Strategy as Independent Executive Advisory Network member. Cell and gene therapy executive with earlier Novartis leadership and founding Tmunity Therapeutics. Published experience includes leading Empyrean Neuroscience; historical fundraising is not an SSI fund close.

Hanne Brokopp is published by SSI Strategy as Senior Vice President. European regulatory specialist with pharmaceutical submission, pre-submission, in-licensing and lifecycle-management experience. Current SVP card takes precedence over older VP wording in biography.

Trevor Mill is published by SSI Strategy as Senior Vice President. Drug-development and regulatory executive with neuroscience, psychiatry and rare-disease experience across early research and approvals.

Victoria Oswald is published by SSI Strategy as Senior Vice President. Chemistry PhD and early-development advisor with translational research and pharmaceutical program experience.

Minna Montgomery is published by SSI Strategy as Senior Vice President. Life-sciences advisor working on clinical and regulatory strategy, R&D programs and commercialization planning.

Max Craig is published by SSI Strategy as Senior Vice President. Consulting executive supporting medical-affairs strategy, launch preparation and cross-functional pharmaceutical operations.

Jacqui Levine is published by SSI Strategy as Senior Vice President. Management consultant with experience helping life-sciences organizations navigate organizational and development transitions.

Madhav Gurijala is published by SSI Strategy as Senior Vice President. Leads SSI’s corporate-development ventures group, strategic-investment decisions and venture-fund relationships. Biotech operator with development and operations experience; unnamed strategic investment fund size and legal vehicle are undisclosed.

Leah Damesek is published by SSI Strategy as Senior Vice President. Clinical, medical and regulatory program leader with earlier Huron Consulting experience and Vanderbilt healthcare-policy education, supporting IND preparation and governance.

Kate Goldstein is published by SSI Strategy as Senior Vice President. Life-sciences organizational consultant who joined SSI in 2011 after Deloitte strategy and operations work. Leads functional-service growth and M&A initiatives.

Heather Paden is published by SSI Strategy as Senior Vice President. Healthcare and pharmaceutical operating leader with experience supporting medical and development functions.

Jen Seda is published by SSI Strategy as Senior Vice President. Medical executive with experience leading clinical and medical teams through therapeutic development.

Benit Maru is published by SSI Strategy as Senior Vice President. Physician, neuroimmunologist and health economist working on rare-disease clinical programs, gene therapies, real-world evidence and health-technology assessments.

Amit Patel is published by SSI Strategy as Senior Vice President. Pharmacist and pharmacovigilance leader, formerly President of Fiore Healthcare Advisors before SSI’s 2021 acquisition of that consultancy.

Adriana Valenciano is published by SSI Strategy as SVP Business Consulting. Named leader of SSI’s business-consulting function. The current individual popup does not publish additional personal background; no education or prior employers inferred.

Laurie Smaldone Alsup is published by SSI Strategy as SVP Regulatory Science. Physician and regulatory-science leader advising on clinical development, regulatory pathways and innovative therapeutic programs.

Delphine Moreau is published by SSI Strategy as EVP Medical Services. Medical-affairs and pharmaceutical executive with experience in Europe and the United States, supporting medical teams and clinical strategy.

Victoria Benech is published by SSI Strategy as Chief Operating Officer. Life-sciences strategy and operations advisor helping biotech organizations manage clinical-development and organizational change.

Kim Kushner is published by SSI Strategy as Chief Business Officer. Public-health trained business leader overseeing SSI growth and client relationships; published outside affiliations include Yale lecturing and American Cancer Society governance.

Adam Schwartz is published by SSI Strategy as President. Early SSI team member and life-sciences management consultant with Acquis Consulting experience. Leads organizational planning and cross-functional development operations.

Johan Strömquist is published by SSI Strategy as President & Chief Innovation Officer. Innovation executive and author on AI risk management, with life-sciences regulatory and information-technology experience. Co-founded Metalmind in 2023 and works on generative AI and digital transformation.

Doug Locke is published by SSI Strategy as CEO. Life-sciences consulting leader focused on organizational design, governance and development milestones from proof of concept through first-in-human studies.

Safeguard Scientifics, Inc. is a Pennsylvania corporate investment and holding company founded in 1953 and based in Radnor. It historically provided growth capital and operating expertise to technology businesses in healthcare, financial services and digital media, including artificial-intelligence healthcare software company Aktana. Since January 2018, it has focused on supporting and monetizing existing ownership interests to return value to shareholders rather than making investments in new companies. It delisted from Nasdaq in February 2024, qualified for OTCQX trading as SFES, and terminated SEC registration. Mark Dow became CEO, CFO and secretary in January 2024 through an outsourced Rock Creek Advisors engagement; a May 2026 issuer tax filing confirms his CFO role. It invests corporate capital rather than operating as a conventional externally raised venture fund.

Beth S. Michelson was identified as a Safeguard Scientifics director in its March 2024 annual report. Her current own Cartesian Capital biography describes her private equity background, University of Michigan BA, Columbia MBA and MIA, and CFA designation. Current Safeguard board status beyond the dated primary disclosure remains unconfirmed.

Eric C. Salzman was Safeguard Scientifics’ CEO until December 31, 2023, when its primary filing records the end of his executive position. The firm’s remaining people directory displays his authentic portrait but its CEO title predates Mark Dow’s January 2024 appointment.

G. Matthew Barnard is identified in Safeguard Scientifics’ historical public directory as general counsel and secretary, alongside his authentic portrait. Mark Dow was appointed secretary in January 2024; Barnard’s current employment or general-counsel status has not been verified.

Joseph M. Manko Jr. was identified as Safeguard Scientifics’ board chairman in its March 2024 annual report and in KORU Medical Systems’ April 2025 proxy. His background includes Horton Capital, BZ Fund Management and investment banking.

Mark R. Dow is Safeguard Scientifics’ CEO, CFO and secretary, appointed January 1, 2024 through its Rock Creek Advisors engagement. Safeguard’s May 2026 tax filing confirms his CFO signature. His own Rock Creek biography describes accounting, finance, operations and restructuring experience and degrees from New England College and Northern Vermont University.

Mark A. Herndon was Safeguard Scientifics’ senior vice president and CFO until December 31, 2023, according to its primary filing. The remaining people directory displays his authentic portrait but its title predates Mark Dow’s appointment.

Ross D. DeMont was identified as a Safeguard Scientifics director in its March 2024 annual report, which describes his Rainin Group investment leadership, earlier Midwood Capital management and Dartmouth MBA. Continued board service after this disclosure has not been independently verified from a newer primary directory.

Russell D. Glass was identified as a Safeguard Scientifics director in its March 2024 annual report. It describes his RDG Capital private investment leadership. He is distinct from the technology executive of the same name. Continued board service after this disclosure has not been independently verified from a newer primary directory.

Santé Ventures is an early-stage healthcare and life sciences venture capital firm founded in 2006. It invests nationally in biotechnology, medical technology and digitally enabled healthcare services, with offices in Austin, Texas, and Boston, Massachusetts. The partnership combines investment, medical, scientific and operating expertise to create and support companies addressing unmet clinical needs. Its neuroscience and deep-technology investments include ReEmerge’s investigational cognitive-network restoration platform, Sensorium Therapeutics’ CNS drug discovery and RapidPulse’s stroke-treatment technology. Santé co-led ReEmerge’s USD37 million Series A announced September 15, 2026. Its fifth venture fund closed with USD330 million in committed capital on February 2, 2026, exceeding the USD300 million target. The wider Santé platform also operates a distinct public-securities strategy, Santé Capital, using proprietary MindRank machine learning and data-science software; that strategy is not treated as an additional venture fund or private-company investment. Current named team roles distinguish venture partners, advisers and fellows from full-time investment staff. This US manager at sante.com is separate from the pre-existing company record at santehq.com.

Orbio AI builds an AI-native HR system for enterprises with large frontline workforces. Its agents automate candidate screening, conversational interviews, scheduling and onboarding, and help HR teams follow employee engagement and retention. Candidates communicate through voice, text, WhatsApp and email in multiple languages; integrations connect the workflows and talent data to existing HR systems. Its HR Agent also lets recruiters manage pipelines and follow-ups through Microsoft Teams, Slack and WhatsApp.

Former President of Microsoft Spain (2021–2025) and Vice President on Microsoft’s EMEA leadership team. Supports market expansion and strategic partnerships at HappyRobot.

Previously co-founder and CTO of Nucoro, acquired by Backbase.

Previously a Commercial Lead at Palantir Technologies. Leads EMEA go-to-market strategy, customer relationships and regional operations.

Previously co-founder of Cobee, acquired by Pluxee.

Previously CEO and co-founder of Colvin.

Amy Olah is listed by CIBC Innovation Banking as Managing Director, Head of Venture Banking, based in Toronto. She leads venture-banking origination and financing structures for Canada and the US West Coast.

Sean Duffy is listed by CIBC Innovation Banking as Managing Director, Head of UK and Europe, based in London. He joined in 2021 to open the London office after a banking and technology career.

Tej Sahi is listed by CIBC Innovation Banking as Managing Director, Head of Fund Finance, based in New York. He joined in 2020 to establish the unit’s fund-finance group, including subscription, capital-call and management-company financing.

Andrew Kirk is listed by CIBC Innovation Banking as Managing Director, Southeast Region Lead, based in Atlanta. His financial-services career spans more than two decades; his CIBC coverage includes B2B software and venture debt.

Walt Sparks is listed by CIBC Innovation Banking as Executive Director, Head of Syndications, based in Durham. His earlier roles included credit analysis and portfolio management at Square One Bank.

Jonathan Schupack is listed by CIBC Innovation Banking as Managing Director, based in Austin. He leads technology lending for Texas and the Mountain States.

Christopher De Ayala is listed by CIBC Innovation Banking as Director, based in Austin. He joined in 2025 and originates early-stage and growth financing in Texas from Austin.

Graham Quisenberry is listed by CIBC Innovation Banking as Director, Life Sciences and Healthcare, based in Boston. He joined the healthcare and life-sciences team in 2021 and finances growth-stage healthcare businesses.

SSI Strategy LLC is a life-sciences strategic consulting and drug-development company headquartered in Morristown, New Jersey, with additional UK, Swedish and German offices. Its historical holding company was SSI Strategy Holdings LLC. It combines business consulting with clinical development, medical affairs, pharmacovigilance, regulatory science and program leadership for biotechnology companies. SSI is a corporate strategic investor, distinct from Summit Strategic Investments, SSI Investment Management and similarly abbreviated organizations. Madhav Gurijala leads its corporate-development ventures group and investment decisions for an own strategic investment fund whose public legal name, size and closing dates are undisclosed; no externally marketed VC fund is inferred. Its AI and neuroscience exposure includes Johan Strömquist’s AI risk and innovation leadership, neuroimmunology expertise from Benit Maru, neuroscience and psychiatry drug-development work from Trevor Mill, and the digital visual-neuroplasticity therapeutic company Luminopia, which names SSI as a seed-extension investor. The current public directory identifies 21 distinct leadership professionals, ten independent Executive Advisory Network members and fifteen NDA regulatory advisory experts; independent network affiliations do not assert employment or personal cash tickets. Amulet Capital made SSI’s first institutional growth investment in December 2020 at an undisclosed price. Clinigen announced its acquisition in September 2025 and confirmed completion on November 21, 2025; the acquisition is separate from startup fundraising and is not assigned an invented deal value.

Julie Silva is listed by CIBC Innovation Banking as Executive Director, Life Sciences and Healthcare, based in Boston. She joined the healthcare and life-sciences team in 2023 and structures debt financing for the sector.

Andrew Phillips is listed by CIBC Innovation Banking as Managing Director, Head of Sponsor Finance, based in Boston. He leads sponsor finance from Boston, focusing on investor-backed technology and software companies.

George Bixby is listed by CIBC Innovation Banking as Director, based in Boston. He joined Boston’s innovation banking team in 2023 and works with technology businesses in New England.

Andrew Schwartz is listed by CIBC Innovation Banking as Managing Director & Market Lead, based in Chicago. He helped establish The PrivateBank’s technology banking group in 2015 before that bank was acquired by CIBC.

Youssef Kabbani is listed by CIBC Innovation Banking as Managing Director, based in Menlo Park. He entered CIBC when it acquired Wellington Financial in 2018 and covers West Coast clients.

Brittany Blanco is listed by CIBC Innovation Banking as Director, based in Menlo Park. She works with California technology businesses through startup, growth and public-company stages.

Sean Thompson is listed by CIBC Innovation Banking as Managing Director & Market Lead, based in San Francisco. He moved to CIBC in 2023 after more than a decade at Silicon Valley Bank.

Paul Gibson is listed by CIBC Innovation Banking as Managing Director, Head of US East Coast Venture Banking, based in Reston. His venture-banking career began in California in 2000 and includes private-credit and bank leadership.

Sarah Perkins is listed by CIBC Innovation Banking as Director, Life Sciences and Healthcare, based in San Francisco. She joined CIBC in 2023 following work on healthcare and life-sciences transactions at Hercules Capital.

Caroline Tkatschow is listed by CIBC Innovation Banking as Managing Director, based in New York. Her sponsor-finance work supports investors and portfolio companies with non-dilutive growth financing.

Diego Recinos is listed by CIBC Innovation Banking as Director, based in Reston. He joined in 2021 and originates Mid-Atlantic financing; his earlier work included Deutsche Bank investment banking.

John Flemming is listed by CIBC Innovation Banking as Managing Director, based in Seattle. He joined CIBC in 2019 after almost sixteen years at Wells Fargo.

Paul McKinlay is listed by CIBC Innovation Banking as Executive Managing Director, Head of Innovation Banking, based in Toronto. He was a founding member of CIBC’s innovation banking team and now leads the unit.

Ravi Patel is listed by CIBC Innovation Banking as Managing Director, Head of Portfolio and Credit Solutions, based in Toronto. He entered CIBC through its MBA rotation program and now leads portfolio and credit solutions.

Robert Rosen is listed by CIBC Innovation Banking as Managing Director, based in Toronto. He joined CIBC in 2018 after leading Comerica Bank Canada’s technology and life-sciences practice.

Adam Weiers is listed by CIBC Innovation Banking as Managing Director, based in Toronto. Since joining the unit in 2018, he has worked with software investors and businesses on both sides of the Canada-US border.

Ab Makalo is listed by CIBC Innovation Banking as Director, based in Toronto. He began at CIBC in 2014 and has experience in credit investment across technology and other middle-market sectors.

Eric Laflamme is listed by CIBC Innovation Banking as Managing Director, based in Montreal. His commercial-banking experience includes Canadian and international innovation businesses.

Joe Timlin is listed by CIBC Innovation Banking as Managing Director, based in Vancouver. He joined in 2018 after a technology-investing career at BDC Venture Capital and GrowthWorks Capital.

Charlotte Goggin is listed by CIBC Innovation Banking as Director, based in London. She joined in 2022 to work on venture and growth debt for European technology businesses.

Niramay is listed by CIBC Innovation Banking as Executive Director, based in Toronto. The bank publishes him under the single name Niramay; his work covers arranging financing for innovation businesses.

Tom Dods is listed by CIBC Innovation Banking as Executive Director, based in London. He joined the London office in 2022 after working in technology and media relationship banking.

Joshua Olawale is listed by CIBC Innovation Banking as Director, based in Toronto. He provides growth financing for venture- and growth-equity-backed software companies in North America and Europe.

Jason Nardari is listed by CIBC Innovation Banking as Managing Director, Portfolio Management & Strategy, based in Toronto. He arrived with Wellington Financial in 2018 and previously headed the unit’s underwriting operation.

Kurt Nichols is listed by CIBC Innovation Banking as Head of US Early Stage & Venture Credit Solutions, Innovation Banking, based in Chicago. He joined the unit in 2021 and focuses on credit for early-stage and venture-backed US companies.

Alex Grinchteine is listed by CIBC Innovation Banking as Executive Director, Portfolio Management, based in Toronto. He entered CIBC through the Wellington Financial acquisition in 2018 and works on its innovation lending portfolio.

ReEmerge, Inc. is an Edina, Minnesota medical-technology company developing Cognitive Network Restoration Therapy (CNRT) for persistent cognitive impairment after traumatic brain injury. Its deep-brain-stimulation approach targets the central thalamus and underperforming neural circuits involved in attention and executive function. The company licenses foundational intellectual property developed through research at Weill Cornell Medicine, with scientific collaborators at Stanford and the University of Utah. CNRT is investigational and has no commercial approval. ReEmerge’s current website names four executive leaders and four scientific co-founders: Nicholas Schiff, Jaimie Henderson, Jonathan Baker and Christopher Butson. It announced a closed USD37 million Series A on September15,2026, co-led by U.S. Venture Partners and Santé, with Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group and Dendrion Ventures participating. Proceeds support a multicenter traumatic-brain-injury clinical study, technology development and clinical and regulatory operations. The company’s founding year and earlier cash-financing history remain unverified; university translational support and licensing are not presumed company equity investments. It is distinct from the Maryland career-coaching business ReEmerge, LLC.

Vice President of Analytics and Strategy at ReEmerge. Holds a master’s degree, as published in the company’s current management directory.

Scientific co-founder of ReEmerge and a medical-device researcher. Holds the endowed chair in Neurotherapeutics at the University of Florida and a PhD, as published in the company’s current directory.

Eva Chickering is listed by CIBC Innovation Banking as Executive Director, based in New York. She moved to CIBC in 2026 after a decade at Standard Chartered.

Scientific co-founder of ReEmerge and a Stanford neurosurgeon. Holds the John and Jene Blume–Robert and Ruth Halperin professorship in Stanford’s Department of Neurosurgery.

Scientific co-founder of ReEmerge and an Assistant Professor of Neuroscience at Weill Cornell Medicine’s Feil Family Brain and Mind Research Institute. Holds a PhD.

Senior Vice President of Clinical Affairs and Operations at ReEmerge. Holds a master’s degree, as published in the company’s current management directory.

Senior Vice President of Research and Development at ReEmerge. Published in the company’s current executive team directory supporting its deep-brain-stimulation technology.

Scientific co-founder of ReEmerge and a Weill Cornell Medicine neurologist and neuroscientist. Holds the Jerold B. Katz professorship and researches restoration of cognitive function after brain injury.

Chief Executive Officer at ReEmerge, leading development of its investigational Cognitive Network Restoration Therapy for chronic cognitive impairment after traumatic brain injury.

Sean Foy is listed by CIBC Innovation Banking as Executive Director, Credit Solutions, based in Toronto. Since entering CIBC in 2011, he has worked in commercial banking, credit risk and innovation financing.

Published Neo-Bionica white-paper coauthor and director of R&D. Biomedical engineer with experience in active implantable neurotechnology and Synchron. Not named in the current main team directory, so current employment is unconfirmed.

Ian Curry is listed by CIBC Innovation Banking as Managing Director & Head of Sponsor Finance Credit Solutions, based in Toronto. He joined CIBC in 2013 and worked in global markets and corporate banking before leading sponsor-finance credit work.

John Blakeley is a life-sciences technology commercial executive and board adviser. PharmaForceIQ and Eir Partners announced his appointment as PharmaForceIQ Chairman in September2024 alongside Eir’s majority growth recapitalization. Eir’s original published biography names him an operating partner and board chair of Gifthealth and PharmaForceIQ, with prior commercial leadership as CALYX Chief Commercial Officer, CRF Health Chief Business Officer, Greenphire Chief Commercial Officer and ERT Executive Vice President and Chief Commercial Officer. The original Eir affiliation is qualified as historical source-published information because he is absent from the replacement current firm roster. An authentic personal portrait was not verified.

Initial chair of Neo-Bionica, announced in 2021 by joint-venture partner Bionics Institute. Medtech entrepreneur and co-founder/former CEO of LBTInnovations. The current Neo-Bionica directory names Emma Cleary as chair; no exact handoverday inferred.

Former Neo-Bionica chief technology officer; his own 2026 post states he finished the role in April. Published company white paper describes two decades of Class II/III device development and leadership at Siemens Healthcare and Advanced Bionics.

Neo-Bionica non-executive director with experience leading technology businesses. Previously senior vice president at Leica Biosystems with responsibility for advanced diagnostics.

Chair of Neo-Bionica according to its current official board directory, which publishes her authentic portrait. No undisclosed professional qualifications or appointment date are inferred.

John Turner is listed by CIBC Innovation Banking as Director, based in Austin. He entered CIBC in 2022 and has worked on venture and sponsor finance across stages of company growth.

Non-executive director of Neo-Bionica representing the University of Melbourne. The company identifies him as head of enterprise partnerships and innovation initiatives at the university, with biotechnology strategy and business-development experience.

Atin Garg is listed by CIBC Innovation Banking as Managing Director, based in New York. He leads venture banking in New York, covering founders’ and investors’ financing and treasury needs.

Biomedical engineer and Sim 4 Life modelling specialist at Neo-Bionica. Previously an R&D engineer with Synchron and a postdoctoral researcher at the universities of Sydney and Melbourne, with neural-interface simulation and embedded-systems experience.

Quality manager at Neo-Bionica. Earlier quality work included CSL, Cochlear and Universal Biosensors, with experience in quality systems, regulated medtech and Lean Six Sigma methods.

Neurotechnology and medical-device consultant at Neo-Bionica. Previously senior director at Galvani Bioelectronics and a deep-brain-stimulation therapy manager at Medtronic. His published expertise covers neuromodulation and implantable-device strategy.

Project coordinator at Neo-Bionica. Her official biography describes project-management experience in public-sector, legal and social settings. The directory’s trailing apostrophe is treated as typography rather than part of the surname.

Graduate engineer at Neo-Bionica, working with Class III medical-device design and verification. The company does not disclose his degree institution or an exact appointment date.

Neo-Bionica electrofabrication technician with earlier biomedical manufacturing experience in a good-manufacturing-practice environment.

Vidur Parmar is listed by CIBC Innovation Banking as Managing Director, Life Sciences and Healthcare, based in San Francisco. His CIBC career spans commercial banking, credit risk and leveraged finance, and he now originates West Coast healthcare transactions.

Mechanical engineer at Neo-Bionica, with prior mechanical-engineering work at Hemideina and in public hospitals. No unrelated person with the same name is inferred.

Senior systems engineer at Neo-Bionica. Previously worked on product development at Fisher&Paykel Healthcare.

Senior electronics engineer at Neo-Bionica. His earlier R&D work included Hemideina, Planet Innovation and Blackmagic. The official biography identifies an electronics doctorate.

Principal consultant at Neo-Bionica. His published career includes engineering management at Seer, Hydrix and Cochlear, with expertise in product development and risk controls. The official directory supplies a generic silhouette rather than a genuine headshot.

Neo-Bionica project director with a medtech consulting background in mechatronics and software. Her company white-paper biography describes engineering and computer-science training, more than 15 years of global consultancy and work bringing six medical products to market.

Directs engineering at Neo-Bionica, with previous engineering experience at Cochlear, Saluda and Hemideina. His published background concerns development of Class III implantable medical devices.

Leads senior business development at Neo-Bionica. Previously held executive positions with Medtronic, St Jude Medical and Abbott and worked on commercial introduction of neurostimulation and other implantable-device therapies.

Chief executive of Neo-Bionica. His career includes leadership at Fortive, Danaher and Siemens, including Invetech and Advanced Sterilization Products. Joint-venture partner Bionics Institute reports a doctorate from Le Havre University and international medical-device operating experience.

Finance and governance executive serving as chief financial officer and company secretary of Neo-Bionica. The company describes experience supporting commercial development in biotechnology and life sciences.

Neo-Bionica Pty Ltd is an Australian neurotechnology contract development and manufacturing company established in July 2021 as a joint venture between the Bionics Institute and the University of Melbourne. Its Australian Business Register entry identifies ABN 78 645915699, active from 1 July 2021. Based at St Vincent’s Hospital Melbourne in Fitzroy, with a team in the United States, it helps innovators turn implantable and wearable medical-device concepts into engineered prototypes, devices for first-in-human studies and clinical-grade manufacturing processes. Its capabilities include bioelectronics, neural interfaces, electrode fabrication, implantable power and wireless systems, firmware, miniaturisation, computational modelling, system integration, high-reliability assembly, hermetic packaging and precision machining. The company reports an ISO 13485-certified quality system and ISO 7 cleanrooms, alongside laser seam welding and hermeticity testing. Its work is relevant to neuroscience and deep technology through active implantable neurotechnology, brain-computer interfaces, neurostimulation and bionic medical devices; engineering and manufacturing capability does not establish clinical approval of every client’s device. The current main directory names 18 leadership, engineering and board members, including CEO Ludovic Labat and chair Emma Cleary. White-paper author Gil Rind is documented with a qualified published affiliation because he is absent from the current main directory. Former CTO Uli Gommel states that he ended the role in April 2026; founding chair Lusia Guthrie is recorded historically. Breakthrough Victoria announced a specific AUD 5 M convertible-note investment on 16 May 2024. Separate public support includes an AUD 4 M Victorian Higher Education State Investment Fund facility/research/voucher allocation at the 2021 opening and a federal Industry Growth Program Project Andromeda grant of AUD 250 K excluding GST, announced 9 January 2025. These government grants are recorded separately from the convertible note. A published client testimonial about securing 1 M belongs to Kali Healthcare, and early Ian Potter Foundation funding went to the Bionics Institute’s predecessor project; neither is extra Neo-Bionica equity financing.

CIBC Innovation Banking is the technology, life-sciences and venture-financing banking unit and shared service brand of Canadian Imperial Bank of Commerce (CIBC) and CIBC Bank USA. Launched in 2018 following CIBC’s acquisition of Wellington Financial assets, it serves early-stage, growth-stage and public companies and the venture investors supporting them across North America, the UK and Europe. It provides venture debt, growth financing, sponsor finance, fund finance, treasury services and strategic banking advice. Its healthcare practice supports medical devices, life sciences and healthcare technology; its technology practice includes AI and software businesses. The unit’s own current directory publishes 40 professionals, led by Paul McKinlay, with specialist leadership for venture banking, sponsor finance, portfolio and credit solutions, syndications, fund finance and UK/Europe. The firm directory category represents this financing unit, not a standalone private-equity partnership or separate incorporated bank. Actual contracting lenders must be verified per transaction: services may be supplied by CIBC or CIBC Bank USA, and the September2019 Aktana announcement identifies the unit but not the exact contracting bank. CIBC closed USD20M debt financing for AI life-sciences company Aktana in September2019. Bank balance-sheet funding, loan-book size, client counts, capital-call facilities, announced credit capacity and predecessor Wellington funds are not treated as new LP fund closes or assumed cash draws.

Deep Track Capital senior controller whose current employer biography documents a previous Broadfin Capital controller role beginning in2014, before joining Consonance Capital in2020. Exact transition days are unpublished.

Octayne Green Fuels turns agricultural residues into biomass fuels for industrial users and energy producers in Southeast Asia. It sources materials such as rice, corn and sugarcane waste and processes them into fuel that can be used in existing facilities as an alternative to coal. Its decentralised production and sourcing model aims to make crop waste commercially useful, reduce open burning and provide industrial customers with reliable, traceable feedstock. The company operates in Indonesia and targets wider regional biomass markets.

Refy provides biomass trading, pricing and supply-chain finance services across Asia. It works with producers, physical traders and industrial buyers of palm kernel shells, rice husks, wood pellets, wood chips, bagasse and other residues. Its products include early payment for receivables, fixed-price offtake and supply contracts, inventory price hedges and index-linked pricing. These tools help suppliers manage working capital and price risk while buyers secure fuel for power plants, cement kilns and industrial boilers. Refy originally developed green asset project financing tools and now presents a specialist biomass market offering.

RegenX developed a regenerative agriculture platform linking food and ingredient buyers with farmers in Southeast Asia. It combined access to buyers and better farm-gate economics with farming guidance, monitoring and traceability to encourage practices that improve soil health and reduce reliance on chemical inputs. Its work included coffee farming in Vietnam, with digital tools to record farm practices and support emissions reporting. The current 100×100 portfolio lists the investment as terminated; ongoing operations and current employment are not established by that historical portfolio record.

Rize provides technology, agronomy support, financing access and market connections for rice farmers in Southeast Asia. It helps farmers adopt practices such as alternate wetting and drying, improved fertiliser use, lower pesticide inputs and crop residue management to reduce emissions and water use while improving farm economics. Its digital platform supports farmer onboarding, input and repayment tracking, agronomist decisions and measurement of environmental outcomes. Rize also connects low-emission rice to buyers through field-level traceability, building an integrated infrastructure for sustainable rice production in Vietnam, Indonesia and other markets.

Founded RegenX and served as chief executive at its 2023 funding announcement; the release also uses the shorter name Bao Nguyen.

Leads Rize’s sustainable rice farming business.

Entrepreneur with structured credit, portfolio management and financial technology experience, including a prior OctiFi exit.

Develops biomass fuel business opportunities and commercial partnerships in Indonesia.

Leads business operations, commercial strategy and partnerships; previously led Rize’s Indonesia operations.

Deep Track Capital operating executive whose current biography documents a former Chief Financial Officer and Chief Compliance Officer role at Broadfin Capital, beginning in April2016. The historical Broadfin affiliation does not imply current employment there.

Leads the agricultural waste to energy business.

Healthcare investor and founder of Broadfin Capital. Broadfin's current website identifies him as founder and portfolio manager and describes his 2020 launch of Broadfin Holdings. SEC filings identify him as managing member of the family office; his general-partner affiliation is historically documented separately.

Robert F. Hess serves Luminopia as Scientific Advisor. The company associates his ophthalmology academic career with McGill University. Its published directory describes the academic title Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

Broadfin Capital, LLC is the healthcare investment manager founded by Kevin Kotler in 2005. Its current website describes the Broadfin Healthcare Funds as operated from 2005 through 2019. Historical SEC disclosures document investments across medical technology, biotechnology and pharmaceuticals, including neurological treatments. It remains a distinct legal identity from Broadfin Advisors, the general-partner affiliate, and Broadfin Holdings, Kotler's family office launched in 2020. Historical staff affiliations are explicitly qualified; assets under management and securities holding values are not fund-close amounts.

Broadfin Holdings LLC is Kevin Kotler's family office, launched in 2020 according to Broadfin's own website. It invests across public and private companies with a healthcare focus and flexibility across sectors and asset classes. Current SEC filings identify Kotler as managing member. It is distinct from the historical Broadfin Capital healthcare-fund manager and Broadfin Advisors general-partner affiliate. The website publishes a shared Broadfin brand and contact channel, but no full current family-office directory or externally raised LP fund close. Reported public holdings are positions rather than new financing commitments.

Eric Singman serves Luminopia as Scientific Advisor. The company associates his ophthalmology academic career with the University of Maryland. Its published directory describes the academic title Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

Krystel Huxlin serves Luminopia as Scientific Advisor. The company associates her ophthalmology academic career with the University of Rochester. Its published directory describes the academic title Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

Broadfin Advisors, LLC is a Delaware general-partner affiliate of Broadfin Capital. Broadfin's own 2020 privacy notice identifies it as the general partner of pooled vehicles; SEC filings distinguish that role from the Capital investment manager. Luminopia names Broadfin Advisors as a participant in its June 2023 Series A for neuro-visual digital therapeutics. Current standalone staffing, independent branding and any dedicated private-fund closing are unpublished or unverified. The displayed image is the authentic shared Broadfin brand, with affiliation explicitly qualified.

Peter Bex serves Luminopia as Scientific Advisor. The company associates his psychology academic career with Northeastern University. Its published directory describes the academic title Chair Of Psychology; this is a publisher biography, not an independently dated institutional appointment.

Marguerite McDonald serves Luminopia as Scientific Advisor. The company associates her ophthalmology academic career with NYU Langone. Its published directory describes the academic title Director, Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

Peter J. McDonnell serves Luminopia as Scientific Advisor. The company associates his ophthalmology academic career with the Wilmer Eye Institute. Its published directory describes the academic title Director, Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

William Dai serves Luminopia as Board Member. The company identifies him as founding managing partner of ShangBay Capital and former chief financial officer of Boston Scientific China. His current own ShangBay biography identifies prior CFO experience at ShangPharma, Nepstar, MicroPort Scientific and Boston Scientific China, earlier Ford treasury experience, and a Michigan State MBA.

Sunny Atwal serves Luminopia as VP of Engineering. Previously served as vice president of technology at Moth+Flame and senior vice president of technology at Littlstar.

Stephanie Roberts serves Luminopia as Head of Market Access. Previously served as senior director of national accounts at Akili and national accounts director at Otsuka and Acorda.

Shelley Hancock serves Luminopia as Sr Director, Medical Affairs. Previously served as senior director of medical and professional affairs at Clearside Biomedical.

Scott Xiao serves Luminopia as Co-Founder and CEO and Board Member. Co-founded Luminopia and is its chief executive officer and a board member. Its published biography lists MIT Technology Review Innovators Under 35 and Forbes 30 Under 30 recognition.

Hank Wu serves Luminopia as COO. Previously served as vice president of digital at Evelo Biosciences and director at Biogen.

Drew Mowery serves Luminopia as VP of Commercial Strategy. Previously served as senior director at Ultragenyx Pharmaceutical and director at bluebird bio and Genentech.

Bruce Kent serves Luminopia as National Sales Director. Former National Sales Director, Specialty Brands, Inside Sales & Marketing Support at Harrow. Former Vice President, Delta Point.

Brion Raymond serves Luminopia as CBO. Former CCO at Clearside Biomedical. Former Director at Genentech.

Luminopia, Inc. is a Cambridge, Massachusetts medical-device company developing prescription digital therapeutics for neuro-visual disorders. Its commercial amblyopia therapy uses proprietary video-processing algorithms and a virtual-reality headset to encourage use of the weaker eye and binocular visual integration while children watch licensed programming at home. FDA 510(k) clearance K243819, decided April 9, 2025, covers patients aged 4 to under 13 with amblyopia associated with anisometropia and/or mild strabismus, as an adjunct to full-time refractive correction under professional prescription. This clearance extends the earlier 2021 De Novo authorization; clinical and commercial claims are qualified as issuer statements. Neuroscience relevance arises from visual processing and binocular therapy; the published algorithms do not by themselves establish artificial-intelligence use. Delaware incorporation in 2015 is documented in the issuer’s SEC filing.

Matt Forman is Vice President, Finance at Eir Partners. Finance professional with earlier Cano Health accounting leadership and PwC experience. Holds Florida State accounting degrees and an active Florida CPA qualification.

Mike Huxsol is Chief Financial Officer & Chief Compliance Officer at Eir Partners. Oversees firm financial and compliance matters; joined in 2024 following private-equity finance experience including Baird Capital and PwC. Holds Wisconsin–Whitewater accounting degrees and an inactive Wisconsin CPA qualification. Current title includes CCO, unlike the older manager page.

Sebastian de la Torre is Associate at Eir Partners. Supports investments and portfolio initiatives with earlier Martis Capital and Bank of America investment-banking experience. Vanderbilt economics graduate.

DJ McFarland is Associate at Eir Partners. Supports investment execution and portfolio initiatives following William Blair healthcare technology M&A experience. Indiana University Kelley finance graduate.

Jake Robbins is Associate at Eir Partners. Supports healthcare investments following Welsh, Carson, Anderson & Stowe and Solomon Partners healthcare M&A work. University of Pennsylvania international-relations graduate.

Liam Dahlberg is Associate at Eir Partners. Supports healthcare investment execution following Siris Capital and UBS financial sponsors and leveraged-finance experience. University of Georgia business graduate.

Alex Antwan is Senior Associate at Eir Partners. Sources and executes healthcare technology investments and supports growth and M&A. Joined Eir in 2021; earlier Ziegler and Truist advisory experience and Miami University finance education.

Arvind Iyengar is Senior Associate at Eir Partners. Healthcare technology investment professional with earlier Vector Capital, Corsair Capital and Lazard technology M&A experience. University of Chicago economics graduate.

Brandon Faresich is Vice President at Eir Partners. Investment professional with earlier Rubicon Founders, Court Square Capital and Bank of America Merrill Lynch experience. Holds a Wharton MBA and Notre Dame finance degree.

Jacob Brackmann is Vice President at Eir Partners. Healthcare investment professional with earlier Greater Sum Ventures and Founders Advisors experience; University of Alabama finance and accounting graduate education.

Thomas B. Raterman, also known as Tom Raterman, formerly served as Runway Growth Finance’s Chief Financial Officer, Chief Operating Officer, Treasurer and Secretary. He retired from the BDC officer roles effective June 30, 2026 and became Vice Chairman of the external adviser, Runway Growth Capital. His historical company officer role is retained separately from that current adviser function.

Julie Persily has served on Runway Growth Finance’s board since 2017 and is an independent director. She formerly co-led leveraged finance at Citigroup and Nomura and worked at Bankers Trust. She also serves on Investcorp Credit Management BDC’s board. She holds a BA in economics and psychology and an MBA from Columbia. Runway’s current chairman is Ted Goldthorpe; an older paragraph calling her chairman is stale.

Robert Warshauer joined Runway Growth Finance’s board in 2025 as an independent director. He formerly led BLST Holdings and worked in investment banking and restructuring at Imperial Capital, Kroll Zolfo Cooper and Ernst & Young. He holds a business degree from Bucknell and an MBA from NYU. Other current BDC biographies qualify his BLST CEO position as former.

Yegor Elkin is Director at Eir Partners. Sources and executes healthcare investments and supports portfolio growth. Prior Madison Dearborn, MSD Partners and Deutsche Bank experience; Notre Dame finance degree. Current Director title supersedes older manager-site Vice President biography.

Gary Kovacs has served as an independent director of Runway Growth Finance since 2016. He formerly led Accela, AVG Technologies and Mozilla and held technology leadership roles at SAP/Sybase, Adobe/Macromedia and IBM. He retired from Accela in January 2024; older Runway biographies describe that former CEO position as current. He holds commerce and MBA degrees from the University of Calgary.

Kevin McClellan is Vice President, Business Development at Eir Partners. Leads firm-wide business development and sourcing, with prior Waud Capital Partners, LaSalle Network and Auctus Capital Partners experience. University of Arizona business graduate.

Alex Duka, also known as Alexander Duka, joined Runway Growth Finance’s board in 2025 as an independent director. He formerly worked for Citigroup for two decades and retired from its Financial Institutions banking group in 2017. He later led corporate development at Acceleration Bay. He holds undergraduate and MBA degrees from Rutgers.

Catherine Frey is an independent Runway Growth Finance director who joined its board in 2025. She co-founded F2P Ventures and previously worked at MatlinPatterson, Bear Stearns and Morgan Stanley. In September 2026 the WTA appointed her a player representative on its board and confirmed her Runway board role.

John Woody is Operating Partner at Eir Partners. Healthcare technology entrepreneur and operating partner who partnered with Brett Carlson during Eir’s first year. Previously led TransUnion healthcare initiatives and worked on Financial Healthcare Systems. Holds Duke biomedical and mechanical engineering education.

Jennifer Kwon Chou joined Runway Growth Finance’s board in 2025 as an independent director. She is a co-founder, President and Partner of Torch Key Asset Management and a senior adviser to The Gores Group. She formerly led strategy at Gores and worked at Sterling Partners and Lehman Brothers. She studied at the University of Pennsylvania and Kellogg.

Tim Fairbanks is Operating Partner & Head of Operations at Eir Partners. Former finance and operating executive at NationsHealth, Convey Health Solutions and Gainwell Technologies. Florida Atlantic University finance graduate with public-offering and acquisition integration experience.

Ted Goldthorpe chairs Runway Growth Finance’s board, which he joined in 2025. He co-founded BC Partners Credit in 2017 and leads that business. He previously held leadership roles at Apollo Investment Corporation and Apollo Investment Management and worked at Goldman Sachs. He holds a commerce degree from Queen’s University.

Avisha Khubani is Chief Credit Officer of Runway Growth Capital and appears in the BDC’s public management directory in that adviser capacity. She joined Runway in 2018 and previously worked in valuation at Duff & Phelps. She is a CFA charterholder, holds an MBA from NYU Stern and an undergraduate degree from Montclair State.

Todd Leri is Operating Partner at Eir Partners. Former CareBridge chief growth officer and early employee; earlier founding-team commercial experience at Remedy Partners. University of Pennsylvania graduate.

Alan Huffman is Operating Partner at Eir Partners. Healthcare technology leader with former CareBridge, Aspire Health and Main Street Health technology leadership, including EHR, analytics and AI operational tools. Holds a Washington University in St. Louis computer-science master’s degree.

Colleen Corwell is Runway Growth Finance’s Chief Compliance Officer and an outsourced compliance executive. She is a Managing Director and head of US Financial Services Compliance and Regulation at Kroll, with experience serving investment advisers, investment companies and broker-dealers. She holds a BA from William and Mary and an MBA from Touro University.

Carmela Thomson became Chief Financial Officer, Treasurer and Secretary of Runway Growth Finance effective June 30, 2026. She joined the adviser in 2021 and previously worked as a senior audit manager at KPMG. She is a CPA and holds a degree in accounting and economics from Loyola University Chicago.

Jeff Martin is Operating Partner at Eir Partners. Healthcare and financial-services finance executive with prior Equian CFO experience and a Purdue degree. The current roster does not retain the older Chief Compliance Officer title; no current external employer appointment inferred.

David Spreng founded Runway Growth Capital in 2015 and is President, a director and, from August 2026, Co-CEO of the externally managed BDC Runway Growth Finance. His investing background includes venture capital and growth lending. He also co-founded Decathlon Capital Partners. The adviser Co-CIO role is separate from his BDC executive positions.